Biogen Q2 Results Top Estimates; Boosts FY25 Outlook

(RTTNews) - Biotechnology company Biogen, Inc. (BIIB) reported Thursday that net income attributable to the company for the second quarter grew to $634.8 million or $4.33 per share from $583.6 million or $4.00 per share in the prior-year quarter.

Excluding items, adjusted earnings for the quarter were $5.47 per share, compared to $5.28 per share in the year-ago quarter.

On average, 26 analysts polled expected the company to report earnings of $3.87 per share for the quarter. Analysts' estimates typically exclude special items.

Total revenue for the quarter grew 7 percent to $2.65 billion from $2.46 billion in the same quarter last year. Revenues were up 8 percent in constant currency. Analysts expected revenues of $2.32 billion for the quarter.

Looking ahead to fiscal 2025, the company now projects adjusted earnings in a range of $15.50 to $16.00 per share on total revenue of approximately flat at constant currency.

Previously, the company expected adjusted earnings in a range of $14.50 to $15.50 per share on a total revenue decline in the mid-single digits at constant currency to reflect the $165 million upfront transaction payment to Stoke and more favorable foreign exchange.

The Street is looking for earnings of $14.64 per share on a revenue decline of 4.31 percent to $9.26 billion for the year.

The company said tThe U.S. and international tariff landscape remains uncertain, and this guidance does not include contemplation of any new tariffs.

For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com